Navigation Links
ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
Date:1/4/2008

DENVER, Jan. 4 /PRNewswire/ -- ARCA Discovery Inc., a privately held biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced Richard B. Brewer, President and Chief Executive Officer, will present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8 at 2:00 PM PT.

The JPMorgan Healthcare Conference will be held January 7-10, 2008 at the Westin St. Francis in San Francisco, California.

About ARCA Discovery, Inc.

ARCA Discovery, Inc. is a privately-held biopharmaceutical company based in Denver, Colorado developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's first product is bucindolol, a next generation beta-blocker for chronic heart failure, which promises to be the first personalized, genetically-targeted cardiovascular therapy. ARCA plans to file for FDA approval of bucindolol in 2008, and to leverage its platform to develop other pharmacogenetic therapies for cardiovascular diseases. The Company recently closed a Series B round of $18 million, led by new investors Skyline Ventures and InterWest Partners. ARCA completed a $15 million Series A round in 2006 led by Atlas Venture and Boulder Ventures, which also participated in the Series B round.

About Bucindolol

ARCA has exclusive worldwide rights to bucindolol, a next generation beta-blocker for chronic heart failure. ARCA's cardiovascular platform combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development, in a unique approach that enables the efficient identification of pharmacogenetic targets. Applying this approach to bucindolol, ARCA has identified pathways affecting bucindolol response that are modulated by common genetic variations. This discovery is supported by substantial Phase 3 data, and will allow a physician to determine whether bucindolol is the right therapy for a patient with a simple genetic test. ARCA has partnered with Laboratory Corporation of America to develop the bucindolol genetic test. Prescribed by using this test, bucindolol could have significant advantages for many chronic heart failure patients. With experience in commercializing cardiovascular products, ARCA plans to market bucindolol in the U.S. through its own sales force.


'/>"/>
SOURCE ARCA Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
2. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
5. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
6. Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference
7. Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference
8. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
9. Xoft to Present at the 26th Annual JPMorgan Healthcare Conference
10. Danaher to Present at J.P. Morgan Healthcare Conference
11. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 25, 2017 , ... Throughout this webinar, participants will learn ... development and economic goals were achieved in both industry and academic settings. Attendees ... along with techniques for scaling production of mesenchymal stem cells (MSCs) and new ...
(Date:5/24/2017)... ... 24, 2017 , ... Benchworks announced that its ... the Healthcare Businesswomen’s Association (HBA). Nominated by chapter president Donna Grande, ... in person once each quarter and holds monthly conference calls. In addition, the ...
(Date:5/24/2017)... and WASHINGTON, DC, USA (PRWEB) , ... May 23, 2017 , ... ... of the economy as well as an enabler of life-saving medical and other vital ... optics and photonics . They joined others in the scientific community today in responding ...
(Date:5/23/2017)... Canada (PRWEB) , ... May 23, 2017 , ... ... Firmex FileSend, a cloud-based file transfer solution that makes it easy for organizations ... without having to worry about cumbersome FTP software or email file size limitations. ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):